New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
16:05 EDTBIND, AMGNBIND Therapeutics, Amgen will not exercise development option
BIND Therapeutics (BIND) announce the completion of its collaborative research program with Amgen (AMGN) originally entered into in January 2013. Amgen and BIND have notified each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. “The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen. Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued,” said Scott Minick, Chief Executive Officer of BIND Therapeutics. “We remain focused on the continued development of our Accurin platform, including our proprietary drug candidate, BIND-014, and our collaborations with AstraZeneca and Pfizer, as well as our recently announced research collaboration with Roche. Furthermore, consistent with our previous guidance, we continue to expect that our cash, cash equivalents and short-term investments, and research development funding that we expect to receive under our existing collaborations, excluding any potential milestone payments, will fund our operating expenses and capital expenditure requirements through at least mid-2015.”
News For BIND;AMGN From The Last 14 Days
Check below for free stories on BIND;AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
16:51 EDTAMGNMarket finishes week lower as Fed, geopolitical worries weigh
Subscribe for More Information
July 30, 2014
18:02 EDTAMGNAmgen shares could gain 25%, Barron's says
Amgen shares could see a 25% gain driven by the company's guidance and restructuring, Barron's argues in its "Barron's Take" column. The stock also has a 1.9% dividend yield, the paper adds. Reference Link
17:12 EDTAMGNOn The Fly: Closing Wrap
Subscribe for More Information
09:38 EDTAMGNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN TWTR NFLX GILD C MA FB RFMD AMGN GNW TSLA
09:04 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTAMGNAmgen price target raised to $138 from $125 at RBC Capital
Subscribe for More Information
06:16 EDTAMGNOptions expected to be active: TWTR BWLD AXP DWA PNRA AMGN X FB
Subscribe for More Information
06:00 EDTAMGNAmgen price target raised to $150 from $143 at Piper Jaffray
Subscribe for More Information
July 29, 2014
18:35 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTAMGNAmgen says total product sales increased 8% in Q2
Total product sales increased 8% for the second quarter of 2014 versus the second quarter of 2013. The increase was mainly driven by ENBREL, Kyprolis, Prolia and XGEVA. Product sales in the second quarter of 2013 included a positive adjustment of $185M to previous estimates for managed Medicaid rebates based on claims experience.
16:21 EDTAMGNAmgen to reduce global workforce by 12%-15%
The company announced a restructuring plan today to invest in continuing innovation and the launch of its new pipeline molecules, while improving its cost structure. Initial efforts include streamlining the organization, reducing layers of management, increasing managerial spans of responsibility and beginning implementation of a revised geographic site plan. As a first step, the company will reduce staff by 2,400-2,900, beginning later this year and continuing through 2015, predominantly in the U.S. This represents approximately 12% to 15% of Amgen’s global workforce. The company will also close its facilities in the states of Washington and Colorado
16:19 EDTAMGNAmgen raises FY14 EPS view to $8.20-$8.40 from $7.90-$8.20, consensus $8.09
Subscribe for More Information
16:16 EDTAMGNAmgen reports Q2 EPS $2.37, consensus $2.07
Reports Q2 revenue $5.18B, consensus $4.9B.
15:53 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:49 EDTAMGNEarnings Preview: Amgen counting on newer drugs to boost sales
Subscribe for More Information
11:11 EDTAMGNAmgen technical comments before results
Subscribe for More Information
July 25, 2014
09:19 EDTAMGNAmgen weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:36 EDTAMGNEMA adopts positive opinion on new indication for Xgeva
Subscribe for More Information
05:35 EDTAMGNBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use